Effect of telmisartan on selected adipokines, insulin sensitivity, and substrate utilization during insulin-stimulated conditions in patients with metabolic syndrome and impaired fasting glucose

European Journal of Endocrinology
Petr WohlTerezie Pelikánová

Abstract

Telmisartan improves glucose and lipid metabolism in rodents. This study evaluated the effect of telmisartan on insulin sensitivity, substrate utilization, selected plasma adipokines and their expressions in subcutaneous adipose tissue (SAT) in metabolic syndrome. Twelve patients with impaired fasting glucose completed the double-blind, randomized, crossover trial. Patients received telmisartan (160 mg/day) or placebo for 3 weeks and vice versa with a 2-week washout period. At the end of each period, a hyperinsulinemic euglycemic clamp (HEC) combined with indirect calorimetry was performed. During HEC (0, 30, and 120 min), plasma levels of adipokines were measured and a needle biopsy (0 and 30 min) of SAT was performed. Fasting plasma glucose was lower after telmisartan compared with placebo (P<0.05). There were no differences in insulin sensitivity and substrate utilization. We found no differences in basal plasma adiponectin, resistin and tumour necrosis factor α (TNFα), but an increase was found in basal leptin, after telmisartan treatment. Insulin-stimulated plasma adiponectin (P<0.05), leptin and resistin (P<0.001) were increased, whereas TNFα was decreased (P<0.05) after telmisartan treatment. Expression of resistin, but ...Continue Reading

References

Mar 1, 1988·Metabolism: Clinical and Experimental·E Ferrannini
Nov 2, 2002·Hypertension·Arya M SharmaFriedrich C Luft
Nov 11, 2003·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Dilek YavuzSema Akalin
Apr 9, 2004·The Journal of Clinical Endocrinology and Metabolism·L K HeilbronnS R Smith
Sep 14, 2004·Journal of Hypertension·Masato FuruhashiKazuaki Shimamoto
Feb 18, 2005·Journal of Hypertension·Karin A M Jandeleit-DahmMark E Cooper
Jun 9, 2005·Hypertension·Ronald ClasenUlrich Kintscher
Jul 28, 2005·Diabetes·Bart Staels, Jean-Charles Fruchart
Mar 28, 2006·The American Journal of Medicine·Theodore W Kurtz
Aug 22, 2006·Metabolism: Clinical and Experimental·Jutta M NagelKlaus G Parhofer
Aug 22, 2006·Metabolism: Clinical and Experimental·Ralf A BenndorfRainer H Böger
Feb 24, 2007·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Roberto Negro, Haslinda Hassan
Mar 10, 2007·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Giuseppe DerosaRoberto Fogari
Apr 3, 2007·Biochemical and Biophysical Research Communications·Akie MoriuchiKatsumi Eguchi
Sep 18, 2007·Clinical Chemistry and Laboratory Medicine : CCLM·UNKNOWN International Federation of Clinical Chemistry and Laboratory Medicine, IFCC Scientific DivisionCas W Weykamp
Sep 23, 2008·Metabolism: Clinical and Experimental·Shinji MakitaMotoyuki Nakamura
Jul 18, 2009·International Heart Journal·Tetsuya NakamuraMasahiko Kurabayashi

❮ Previous
Next ❯

Citations

Dec 14, 2012·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Hisato TakagiUNKNOWN All-Literature Investigation of Cardiovascular Evidence Group
Mar 26, 2013·Journal of the American Society of Hypertension : JASH·Hisato TakagiUNKNOWN ALICE (All-Literature Investigation of Cardiovascular Evidence) Group
Feb 23, 2012·International Journal of Cardiology·Hisato TakagiTakuya Umemoto
Jun 11, 2015·European Journal of Nutrition·Sajjad MoradiArash Hossein-Nezhad
Feb 13, 2021·Biotechnology and Applied Biochemistry·Aswathy R DevanLekshmi R Nath

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.